Preventive Cardiovascular

Impact of PCSK9 Inhibitors

Impact of PCSK9 Inhibitors in Patients

2020, N = 292

Preventive cardiology patients on PCSK9 inhibitors experienced significant reductions in low-density lipoprotein (LDL) cholesterol levels.

HDL = high-density lipoprotein, LDL = low-density lipoprotein

Source: EPIC

Lab values were somewhat limited in 2020 due to COVID-19. Fluctuations in 2020 volumes are a result of significant changes to the number of patients treated, which can be directly attributed to the COVID-19 pandemic.